|Systematic (IUPAC) name|
Vigamox, Moxeza (eye drops)
|Licence data||US FDA:|
|Routes||Oral, IV, local (eyedrops)|
|Bioavailability||86 to 92%|
|Protein binding||30 to 50%|
|Metabolism||Glucuronide and sulfate conjugation
Cytochrome P450 system not involved
|ATC code||J01 S01|
|Molecular mass||401.431 g/mol|
|(what is this?)|
Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent developed by Bayer AG (initially called BAY 12-8039). It is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avelon for oral treatment. In most countries, the drug is also available in parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-(+) bacteria and anaerobes. Because of its potent activity against the common respiratory pathogen Streptococcus pneumoniae, it is considered a "respiratory quinolone."
A United States patent application was submitted on 30 June 1989, for Avelox (moxifloxacin hydrochloride). In 1999 Avelox was approved by the U.S. Food and Drug Administration (FDA) for use in the United States.
In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community acquired pneumonia, complicated and uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. In the US, the marketing approval does not contain these restrictions, though the label contains prominent warnings against skin reactions.
Avelox (moxifloxacin) was launched in the United States in 1999 and is currently[when?] marketed in more than 80 countries worldwide. In the United States, Avelox is marketed by Bayer's partner Merck.
In 2011 the FDA added two boxed warnings for this drug in reference to spontaneous tendon ruptures and the fact that moxifloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and life-threatening breathing problems.
- 1 Medical uses
- 2 Adverse effects
- 3 Contraindications
- 4 Interactions
- 5 Overdose
- 6 Mechanism of action
- 7 Pharmacokinetics
- 8 Susceptible bacteria
- 9 Chemistry
- 10 History
- 11 Patent
- 12 Society and Culture
- 13 References
The initial approval by the FDA (December 1999) encompassed the following indications:
- Acute exacerbations of chronic bronchitis (AECB)
- Acute bacterial sinusitis (ABS)
- Community acquired pneumonia (CAP)
Additional indications were approved by the FDA as follows:
- April 2001: Uncomplicated skin and skin structure Infections (uSSSI)
- May 2004: Community acquired pneumonia caused by multi-drug resistant Streptococcus pneumoniae.
- June 2005: Complicated skin and skin structure Infections (cSSSI)
- November 2005: Complicated intra-abdominal Infections (cIAI).
At the current time,[when?] there are no approved uses within the pediatric population for oral and intravenous moxifloxacin. A significant number of drugs found within this class, including moxifloxacin, are not licensed by the FDA for use in children due to the risk of permanent injury to the musculoskeletal system.
Rare but serious adverse effects that may occur as a result of moxifloxacin therapy include irreversible peripheral neuropathy, spontaneous tendon rupture and tendonitis, hepatitis, psychiatric effects (hallucinations, depression), torsades de pointes, Stevens-Johnson syndrome and clostridium difficile-associated disease (CDAD), and photosensitivity/phototoxicity reactions.
There are only two listed contraindications found within the 2008 package insert:
- "Nonsteroidal anti-inflammatory drugs (NSAIDs): Although not observed with moxifloxacin in preclinical and clinical trials, the concomitant administration of a nonsteroidal anti-inflammatory drug with a fluoroquinolone may increase the risks of CNS stimulation and convulsions."
- "Moxifloxacin is contraindicated in persons with a history of hypersensitivity to moxifloxacin, any member of the quinolone class of antimicrobial agents, or any of the product components."
Though not stated as such within the package insert, ziprasidone is also considered to be contraindicated, as it may have the potential to prolong QT interval. Moxifloxacin should also be avoided in patients with uncorrected hypokalemia, or concurrent administration of other medications known to prolong the QT interval (antipsychotics and tricyclic antidepressants).
Moxifloxacin should be used with caution in patients suffering from diabetes, as glucose regulation may be significantly altered.
Moxifloxacin is also considered to be contraindicated within the pediatric population, pregnancy, nursing mothers, patients with a history of tendon disorder, patients with documented QT prolongation, and patients with epilepsy or other seizure disorders. Coadministration of moxifloxacin with other drugs that also prolong the QT interval or induce bradycardia (e.g., beta-blockers, amiodarone) should be avoided. Careful consideration should be given in the use of moxifloxacin in patients with cardiovascular disease, including those with conduction abnormalities.
Well controlled studies of the safety of moxifloxacin in pregnancy or lactating mothers have not been performed. Animal studies suggest the potential for harm to the fetus in pregnancy, and suggest that moxifloxacin may be excreted into the milk of lactating mothers. Decisions as to whether to continue therapy during pregnancy or while breast feeding should take the potential risk of harm to the fetus or child into account, as well as the importance of the drug to the well being of the mother.
The safety of moxifloxacin in children under age 18 has not been established. Animal studies suggest the potential for musculoskeletal harm in juveniles.
Moxifloxacin is not believed to be associated with clinically significant drug interactions due to inhibition or stimulation of hepatic metabolism. Thus, it should not, for the most part, require special clinical or laboratory monitoring to ensure its safety. Moxifloxacin has a potential for a serious drug interaction with NSAIDS.
Antacids containing aluminium or magnesium ions inhibit the absorption of moxifloxacin. Drugs that prolong the QT interval (e.g., pimozide) may have an additive effect on QT prolongation and lead to increased risk of ventricular arrhythmias. The INR (international normalised ratio) may be increased or decreased in patients treated with warfarin.
"In the event of acute overdose, the stomach should be emptied and adequate hydration maintained. ECG monitoring is recommended due to the possibility of QT interval prolongation. The patient should be carefully observed and given supportive treatment. The administration of activated charcoal as soon as possible after oral overdose may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively." (sic) Quoting from the 29 December 2008 package insert for Avelox.
Mechanism of action
Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, enzymes necessary to separate bacterial DNA, thereby inhibiting cell replication.
Approximately 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation. The cytochrome P450 system is not involved in moxifloxacin metabolism, and is not affected by moxifloxacin. The sulfate conjugate (M1) accounts for approximately 38% of the dose, and is eliminated primarily in the feces. Approximately 14% of an oral or intravenous dose is converted to a glucuronide conjugate (M2), which is excreted exclusively in the urine. Peak plasma concentrations of M2 are approximately 40% those of the parent drug, while plasma concentrations of M1 are, in general, less than 10% those of moxifloxacin.
In vitro studies with cytochrome (CYP) P450 enzymes indicate that moxifloxacin does not inhibit 80 CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, suggesting that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes.
The pharmacokinetics of moxifloxacin in pediatric subjects have not been studied.
The half-life of moxifloxacin is 11.5-15.6 hours (single-dose, oral). Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces). A total of 96% ± 4% of an oral dose is excreted as either unchanged drug or known metabolites. The mean (± SD) apparent total body clearance and renal clearance are 12 ± 2 L/h and 2.6 ± 0.5 L/h, respectively. The CSF penetration of moxifloxacin is 70% to 80% in patients with meningitis.
A broad spectrum of bacteria is susceptible including, but not limited to:
- Staphylococcus aureus
- Staphylococcus epidermidis
- Streptococcus pneumoniae
- Haemophilus influenzae
- Klebsiella spp.
- Moraxella catarrhalis
- Enterobacter spp.
- Mycobacterium spp.
- Bacillus anthracis
Moxifloxacin monohydrochloride is a slightly yellow to yellow crystalline substance.
Moxifloxacin was first patented (United States patent) in 1991 by Bayer A.G., and again in 1997. Avelox was subsequently approved by the U.S. Food and Drug Administration (FDA) for use in the United States in 1999 to treat specific bacterial infections. Ranking 140th within the top 200 prescribed drugs in the United States for 2007, Avelox generated sales of $697.3 million worldwide.
A United States patent application was made on 30 June 1989, for Avelox, Bayer A.G. being the assignee, which was subsequently approved on 5 February 1991. This patent was scheduled to expire on 30 June 2009. However, this patent was extended for an additional two and one half years on 16 September 2004, and as such is not expected to expire until 2012. Moxifloxacin was subsequently (ten years later) approved by the U.S. Food and Drug Administration (FDA) for use in the United States in 1999. There have been at least four additional United States patents filed regarding moxifloxacin hydrochloride since the 1989 United States application, as well as patents outside of the USA.
Society and Culture
Regulatory agencies have taken actions to address certain rare but serious adverse events associated with moxifloxacin therapy.
Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. Similarly, the Canadian label includes a warning of the risk of liver injury.
The U.S. label does not contain restrictions similar to the European label, but a carries a "black box" warning of the risk of tendon damage and/or rupture and warnings regarding the risk of irreversible peripheral neuropathy.
In 2007, the U.S. District Court for the District of Delaware held that two Bayer patents on Avelox are valid and enforceable, and infringed by Dr. Reddy's ANDA for a generic version of Avelox. The district court sided with Bayer, citing the Federal Circuit's prior decision in Takeda v. Alphapharm as "affirming the district court's finding that defendant failed to prove a prima facie case of obviousness where the prior art disclosed a broad selection of compounds, any one of which could have been selected as a lead compound for further investigation, and defendant did not prove that the prior art would have led to the selection of the particular compound singled out by defendant." According to Bayer's press release announcing the court's decision, it was noted that Teva had also challenged the validity of the same Bayer patents at issue in the Dr. Reddy's case. Within Bayer's first quarter 2008 stockholder's newsletter Bayer stated that they had reached an agreement with Teva Pharmaceuticals USA, Inc., the adverse party, to settle their patent litigation with regard to the two Bayer patents. Under the settlement terms agreed upon, Teva would obtain a license to sell its generic moxifloxacin tablet product in the U.S. shortly before the second of the two Bayer patents expires in March 2014.
- hauser. antibiotic basics for clinicians. ISBN 9781451112214.
- Drugwatch. "Avelox Patent Family". Retrieved 16 September 2012.
- "Details for NDA:021085". DrugPatentWatch. Retrieved 17 July 2009.
- "Avelox". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- ^ http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/21085se1-022,21277se1-017ltr.pdf.
- ^ http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/021085s027,029,021277s024,025ltr.pdf.
- "Moxifloxacin: restricted use : MHRA".
- European Medicines Agency (24 July 2008). "European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines". Retrieved 20 July 2009.
- "SYNOPSIS". Retrieved 29 January 2009.
- Karande SC, Kshirsagar NA (February 1992). "Adverse drug reaction monitoring of ciprofloxacin in pediatric practice". Indian Pediatr 29 (2): 181–8. PMID 1592498.
- Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy in a child". Journal of Postgraduate Medicine 53 (2): 144–5. doi:10.4103/0022-3859.32220. PMID 17495385.
- "Center for drug evaluation and research Application number 21-598". Food and Drug Administration (FDA). 15 April 2005. Retrieved 21 July 2009.
- Renata Albrecht (28 July 2004). "NDA 21-085/S-024, NDA 21-277/S-019". Center for Drug Evaluation and Research. Food and Drug Administration (FDA). Retrieved 31 July 2009.
- Renata Albrecht (31 May 2007). "NDA 21-085/S-036, NDA 21-277/S-030". Center for Drug Evaluation and Research. Food and Drug Administration (FDA). Retrieved 31 July 2009.
- Renata Albrecht (15 February 2008). "NDA 21-085/S-038, NDA 21-277/S-031". Division of Special Pathogen and Transplant Products. Food and Drug Administration (FDA). Retrieved 31 July 2009.
- DEPARTMENT OF HEALTH & HUMAN SERVICES (28 February 2008). "NDA 21-085/S-014, S-015, S-017". Food and Drug Administration (FDA). Retrieved 17 July 2009.
- "Risk for Uveitis With Oral Moxifloxacin". JAMA Opthamology online. 2 October 2014.
- Bayer (December 2008). "AVELOX (moxifloxacin hydrochloride) Tablets AVELOX I.V. (moxifloxacin hydrochloride in sodium chloride injection)". Food and Drug Administration (FDA). p. 19. Retrieved 2 November 2010.
- "Moxifloxacin". University of Maryland Medical Center. 2009. Retrieved 22 July 2009.
- Medscape: Medscape Access
- Renata Albrecht (16 May 2002). "NDA 21-085/S-012". Food and Drug Administration (FDA). Retrieved 17 July 2009.
- Drlica K, Zhao X (1 September 1997). "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiol Mol Biol Rev. 61 (3): 377–92. PMC 232616. PMID 9293187.
- "Drug card for Moxifloxacin (DB00218)". Canada: DrugBank. 19 February 2009. Retrieved 3 August 2009.
- Alffenaar J. W. C., van Altena R., Bökkerink H. J (2009). "Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis". Clinical Infectious Diseases 49 (7): 1080–2. doi:10.1086/605576. PMID 19712035.
- "Inventors/Applicants". patentlens.net. 3 October 2006. Retrieved 17 July 2009.
- Ed Lamb (1 May 2008). "Top 200 Prescription Drugs of 2007". Pharmacy Times. Retrieved 21 July 2009.
- "EU agency recommends restricting moxifloxacin use". Reuters. 24 July 2008. Retrieved 21 July 2009.
- US 4990517 A (Feb 1991) Petersen et al. See http://www.patentlens.net/patentlens/search_ajax.cgi?patnum=US+4990517#list US 5051509 A (Sep 1991) Nagano et al. See http://www.patentlens.net/patentlens/search_ajax.cgi?patnum=US+5051509#list US 5059597 A (Oct 1991) Petersen et al. See http://www.patentlens.net/patentlens/search_ajax.cgi?patnum=US+5059597#list US 5395944 A (Mar 1995) Petersen et al. See http://www.patentlens.net/patentlens/search_ajax.cgi?patnum=US+5395944#list US 5416096 A (May 1995) Petersen et al. See http://www.patentlens.net/patentlens/search_ajax.cgi?patnum=US+5416096#list
- Updated Labeling for Antibiotic Avelox (Moxifloxacin) Regarding Risk of Severe Liver Injury / Information Update: 2010-42 For immediate release 22 March 2010 http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2010/2010_42-eng.php
- Renata Albrecht (3 October 2008). "NDA 21-085/S-040, NDA 21-277/S-034". Center for Drug Evaluation and Research. Food and Drug Administration (FDA). Retrieved 31 July 2009.
- Bayer AG (6 November 2007). "Ruling in Bayer's favor over Avelox patents". Bayer. Retrieved 29 August 2009.
- "United States Court of Appeals for the Federal Circuit". uscourts.gov. 28 June 2007. Retrieved 29 August 2009.[dead link]
- Bayer AG (24 April 2008). "Risk Report". Bayer. Retrieved 29 August 2009.